lutetium177labeled
Lutetium-177 labeled refers to compounds where the radioactive isotope Lutetium-177 (¹⁷⁷Lu) is attached to a molecule. This labeling process creates radiopharmaceuticals that can be used in targeted cancer therapy and diagnostic imaging. Lutetium-177 is a beta-emitting isotope with a half-life of approximately 6.7 days, making it suitable for therapeutic applications due to its ability to deliver radiation dose to cancerous cells while minimizing damage to surrounding healthy tissues. The gamma emission from ¹⁷⁷Lu also allows for imaging, enabling physicians to visualize the distribution of the radiopharmaceutical within the body and assess treatment efficacy.
The development of lutetium-177 labeled compounds has been a significant advancement in the field of nuclear
Several lutetium-177 labeled drugs are currently approved and in clinical use for treating various cancers, including